These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

960 related articles for article (PubMed ID: 14692652)

  • 1. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
    Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
    Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-mammary tumor location does not influence prognosis but influences the prevalence of axillary lymph-node metastases.
    Janni W; Rack B; Sommer H; Schmidt M; Strobl B; Rjosk D; Klanner E; Thieleke W; Gerber B; Friese K; Dimpfl T
    J Cancer Res Clin Oncol; 2003 Sep; 129(9):503-10. PubMed ID: 12884027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management and outcomes of isolated axillary node recurrence in breast cancer.
    Konkin DE; Tyldesley S; Kennecke H; Speers CH; Olivotto IA; Davis N
    Arch Surg; 2006 Sep; 141(9):867-72; discussion 872-4. PubMed ID: 16983030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
    White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
    J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
    Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
    Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
    Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
    Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of omission of axillary lymph node dissection after negative sentinel lymph node biopsy: 70-month follow-up.
    Kim HJ; Son BH; Lim WS; Seo JY; Koh BS; Lee JW; Gong GY; Ahn SH
    Ann Surg Oncol; 2010 Aug; 17(8):2126-31. PubMed ID: 20162458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer.
    Hatoum HA; Jamali FR; El-Saghir NS; Musallam KM; Seoud M; Dimassi H; Abbas J; Khalife M; Boulos FI; Tawil AN; Geara FB; Salem Z; Shamseddine AA; Al-Feghali K; Shamseddine AI
    Ann Surg Oncol; 2009 Dec; 16(12):3388-95. PubMed ID: 19655200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
    Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
    Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional nodal recurrence in the management of breast cancer patients with one to three positive axillary lymph nodes. Outcome of patients following tangential irradiation without a separate nodal field.
    Stranzl H; Peintinger F; Ofner P; Prettenhofer U; Mayer R; Hackl A
    Strahlenther Onkol; 2004 Oct; 180(10):623-8. PubMed ID: 15480510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence.
    Shen J; Hunt KK; Mirza NQ; Buchholz TA; Babiera GV; Kuerer HM; Bedrosian I; Ross MI; Ames FC; Feig BW; Singletary SE; Cristofanilli M; Meric-Bernstam F
    Cancer; 2005 Aug; 104(3):479-90. PubMed ID: 15968686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of the axilla in breast cancer: evidences and unresolved issues].
    Fodor J; Polgár C; Péley G; Németh G
    Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement.
    Barranger E; Coutant C; Flahault A; Delpech Y; Darai E; Uzan S
    Breast Cancer Res Treat; 2005 May; 91(2):113-9. PubMed ID: 15868438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.